Home › Neuroendocrine Carcinoma › California
Neuroendocrine Carcinoma clinical trials in California
6 studies for Neuroendocrine Carcinoma are looking for participants at sites in California.
Cities in California
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Los Alamitos Hematology/Oncology Medical Group, Glendale
- MemorialCare Long Beach Medical Center, Long Beach
- Valkyrie Clinical Trials, Los Angeles
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07080242A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Los Angeles Cancer Network, Los Angeles
- Pih Health Hematology Medical Oncology, Whittier
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Duarte
- Crinetics Study Site, Newport Beach
- Crinetics Study Site, Orange
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
- USC Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- St Joseph Heritage Healthcare, Santa Rosa
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.